Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

publishing date : 2022 - 09 - 14    tags : Treatment    save search

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
Published: 2022-09-14 (Crawled : 00:00) - globenewswire.com
MNOV | $1.4 9.6K twitter stocktwits trandingview |
Health Technology
| | O: -0.46% H: 4.65% C: 2.33%

mn-166 treatment patent glioblastoma
USD 7.22 Bn growth expected in Myopia and Presbyopia Treatment Market -- Evolving Opportunities with AbbVie Inc. and Alcon Inc.
Published: 2022-09-14 (Crawled : 21:00) - prnewswire.com
ALC | $79.43 1.22% 760K twitter stocktwits trandingview |
Health Technology
| | O: 0.71% H: 0.82% C: -0.31%
ABBV | News | $165.97 0.8% 3.1M twitter stocktwits trandingview |
Health Technology
| | O: 0.32% H: 2.79% C: 1.8%

treatment expected growth presbyopia market
It All Comes Down To Science And Research With The Efficacy Of Jupiter Wellness’s Lineup Of Skin And Hair Treatment Drugs
Published: 2022-09-14 (Crawled : 19:00) - jupiterwellnessinc.com
WMT | News | $59.39 0.22% 7.1M twitter stocktwits trandingview |
Retail Trade
| | O: 0.1% H: 0.07% C: -1.17%

treatment research skin
Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment
Published: 2022-09-14 (Crawled : 16:00) - biospace.com/
LGND | $72.33 -0.26% 45K twitter stocktwits trandingview |
Health Technology
| | O: 0.44% H: 0.48% C: -2.07%

treatment response cancer esr1 mutation her2- her2
Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis
Published: 2022-09-14 (Crawled : 14:20) - biospace.com/
TMBR | $0.3426 -2.69% 3K twitter stocktwits trandingview |
Health Technology
| | O: 5.69% H: 34.23% C: 7.31%

tmb-001 treatment designation positive
TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS
Published: 2022-09-14 (Crawled : 14:20) - biospace.com/
TCON | $2.01 -4.74% 130K twitter stocktwits trandingview |
Health Technology
| | O: 4.21% H: 1.52% C: -4.04%

treatment fda designation soft tissue fast track designation
Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B
Published: 2022-09-14 (Crawled : 14:00) - biospace.com/
CNTA | $10.42 -1.05% 74K twitter stocktwits trandingview |
Manufacturing
| | O: 0.94% H: 9.53% C: 7.91%

treatment designation drug granted
GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases
Published: 2022-09-14 (Crawled : 14:00) - biospace.com/
IBIO | $1.73 -2.26% 77K twitter stocktwits trandingview |
Health Technology
| | O: -0.97% H: 4.16% C: -4.89%

treatment preclinical
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration
Published: 2022-09-14 (Crawled : 14:00) - biospace.com/
ADVM | $11.065 -0.76% 69K twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 7.55% C: 2.83%

treatment macular trial phase 2
eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
Published: 2022-09-14 (Crawled : 12:20) - globenewswire.com
EFTR | $1.72 -3.37% 78K twitter stocktwits trandingview |
| | O: 3.58% H: 2.95% C: -4.62%

covid-19 treatment trial therapeutics phase 2b
Macular Degeneration Treatment Global Market to Reach $10.65 Billion by 2026 at a CAGR of 7.15%
Published: 2022-09-14 (Crawled : 10:00) - prnewswire.com
GLAXF | $20.2 510 twitter stocktwits trandingview |
Health Technology
| | O: -4.98% H: 7.63% C: 2.67%
NVS | $94.285 1.85% 1.6M twitter stocktwits trandingview |
Health Technology
| | O: -0.55% H: 0.42% C: -0.72%
GSK | $39.585 0.8% 1.1M twitter stocktwits trandingview |
Health Technology
| | O: -0.6% H: 0.41% C: -0.76%
BHC | $8.63 0.35% 2.1M twitter stocktwits trandingview |
Health Technology
| | O: 0.41% H: 11.64% C: 6.22%
RGNX | $15.49 -3.85% 210K twitter stocktwits trandingview |
Health Technology
| | O: 0.38% H: 2.53% C: 1.48%

treatment global macular market
Gainers vs Losers
71% 29%

Top 10 Gainers
AGBA | News | $1.27 217.5% 120M twitter stocktwits trandingview |
Finance

EGOX | $0.0503 39.72% 320M twitter stocktwits trandingview |

RWOD | $10.52 31.56% 5.9M twitter stocktwits trandingview |
n/a

ZCMD | $1.905 31.38% 30M twitter stocktwits trandingview |
Commercial Services

MRDB 4 | $0.536 27.65% 2M twitter stocktwits trandingview |
n/a

BSFC | $0.0822 27.64% 75M twitter stocktwits trandingview |
Manufacturing

TPET | $0.4121 25.68% 45M twitter stocktwits trandingview |
n/a

NVFY | $2.65 25.59% 33M twitter stocktwits trandingview |
Consumer Durables

INDO | $5.1 25.0% 15M twitter stocktwits trandingview |
Energy Minerals

CHRO | $1.53 24.9% 100K twitter stocktwits trandingview |
n/a


Your saved searches
Save your searches and get alerts when important news are released.